ACCELERON PHARMA INC Insider Trading for March 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for March 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | M | 5.08 | 18,750 | 95,250 | 0 | |
| Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | M | 5.08 | 18,750 | 95,250 | 0 | |
| Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | M | 5.08 | 18,750 | 95,250 | 135,481 | 116.7 K to 135.5 K (+16.06 %) |
| Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | M | 5.08 | 18,750 | 95,250 | 135,481 | 116.7 K to 135.5 K (+16.06 %) |
| Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | M | 5.08 | 37,500 | 190,500 | 0 | |
| Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Sell | S | 42.32 | 2,902 | 122,813 | 31,250 | 34.2 K to 31.3 K (-8.50 %) |
| Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Sell | S | 41.34 | 34,598 | 1,430,281 | 34,152 | 68.8 K to 34.2 K (-50.32 %) |
| Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Buy | M | 5.08 | 37,500 | 190,500 | 68,750 | 31.3 K to 68.8 K (+120.00 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,250 | 0 | 6,500 | 5.3 K to 6.5 K (+23.81 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 40.61 | 1,875 | 76,144 | 1,875 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 312 | 0 | 312 | 0 to 312 |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Grant | A | 0.00 | 1,250 | 0 | 31,250 | 30 K to 31.3 K (+4.17 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 1,250 | 0 | 1,795 | 545 to 1.8 K (+229.36 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Grant | A | 0.00 | 1,250 | 0 | 2,500 | 1.3 K to 2.5 K (+100.00 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 2,500 | 1.3 K to 2.5 K (+100.00 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 40.61 | 26,775 | 1,087,333 | 26,775 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 4,463 | 0 | 97,138 | 92.7 K to 97.1 K (+4.82 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Option Exercise | A | 40.61 | 24,375 | 989,869 | 24,375 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Grant | A | 0.00 | 4,063 | 0 | 28,764 | 24.7 K to 28.8 K (+16.45 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Option Exercise | A | 40.61 | 50,000 | 2,030,500 | 50,000 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Option Exercise | A | 40.61 | 28,950 | 1,175,660 | 28,950 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Grant | A | 0.00 | 4,825 | 0 | 57,802 | 53 K to 57.8 K (+9.11 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 40.61 | 30,825 | 1,251,803 | 30,825 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 5,138 | 0 | 47,939 | 42.8 K to 47.9 K (+12.00 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 40.61 | 108,800 | 4,418,368 | 108,800 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 18,100 | 0 | 80,900 | 62.8 K to 80.9 K (+28.82 %) |